{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:18:16Z","timestamp":1792459096018,"version":"4.5.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["No. 20224ACB206008"],"award-info":[{"award-number":["No. 20224ACB206008"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To investigate the efficacy and safety of telitacicept combined with glucocorticoid\/mycophenolate mofetil (GM) versus telitacicept in the treatment of immunoglobulin A nephropathy (IgAN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, multicenter cohort study enrolled patients aged \u2265 18 years with biopsy-proven IgAN who were treated with telitacicept. All participants had a baseline eGFR \u2265 30 mL\/min\/1.73 m\u00b2 and proteinuria excretion \u2265 0.75 g\/day after receiving at least 1 month of optimized supportive treatment. Clinical data were collected over 9 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 256 patients were enrolled in the study, with 125 patients receiving telitacicept monotherapy and 131 patients receiving telitacicept plus GM therapy. The mean age was 39.5 \u00b1 11.6 years, and 100 patients (39.1%) were male. At 9 months, the telitacicept + GM group showed a significantly greater reduction in proteinuria (-1.32 g\/day versus -0.94 g\/day,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001) and exhibited better eGFR slope (2.74 mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      \/year versus -0.56 mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      \/year,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.014) compared to the telitacicept group. Similar reductions in urinary red blood cell count were observed in both groups, but the telitacicept + GM group exhibited a significantly greater median change at 9 months (-35.5\/\u00b5L versus -9.0\/\u00b5L,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.009). Kaplan-Meier analysis revealed a significant benefit for the telitacicept + GM group over telitacicept monotherapy in both complete (54.2% vs. 40.8%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.005) and overall (78.6% vs. 70.4%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.014) remission rates. After adjusting for various factors, multivariable Cox regression analysis indicated a significantly higher likelihood of complete [adjusted HR 2.18 (95% CI 1.46-3.22),\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001] and overall [adjusted HR 1.46 (95% CI 1.08-2.00),\n                      <jats:italic>P<\/jats:italic>\n                      = 0.013] remissions in the telitacicept + GM group at 9 months. Benefits were consistent across subgroups, with no significant interaction effects. Although the telitacicept + GM group was associated with a higher overall incidence of adverse events (28.2% versus 11.2%), no serious adverse events were reported in either group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Telitacicept + GM regimen significantly reduced proteinuria and hematuria, maintained stable renal function in patients with IgAN, with no serious adverse events occurring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1740891","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T06:51:54Z","timestamp":1770792714000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of telitacicept combined with immunosuppressive therapy for IgA nephropathy: a retrospective multicenter cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Fang","family":"Zeng","sequence":"first","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]},{"name":"Department of Nephrology, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University","place":["Ganzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University","place":["Ganzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yebei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Health Management Center, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daijin","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Health Management Center, Jiangxi Provincial People\u2019s Hospital","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengmin","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Jiujiang Hospital of Traditional Chinese Medicine","place":["Jiujiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital of Jiujiang University","place":["Jiujiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital of Gannan Medical University","place":["Ganzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Yingtan 184 Hospital","place":["Yingtan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizhang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Yichun People\u2019 s Hospital","place":["Yichun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University","place":["Ganzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaosi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","article-title":"IgA nephropathy","volume":"9","author":"Stamellou","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02843-X","article-title":"Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort","volume":"403","author":"Wong","year":"2024","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1053\/j.ajkd.2023.12.016","article-title":"Time-varying proteinuria and progression of igA nephropathy: A cohort study","volume":"84","author":"Tang","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment","volume":"21","author":"Cheung","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.12669\/pjms.39.6.8393","article-title":"Efficacy and safety of Telitacicept in patients with IgA nephropathy","volume":"39","author":"Liang","year":"2023","journal-title":"Pak J Med Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.kint.2025.05.028","article-title":"Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy","volume":"108","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"6927","DOI":"10.3390\/jcm12216927","article-title":"A PRoliferation-inducing ligand (APRIL) in the pathogenesis of immunoglobulin A nephropathy: A review of the evidence","volume":"12","author":"Mathur","year":"2023","journal-title":"J Clin Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s40001-023-01320-2","article-title":"Role of telitacicept in the treatment of IgA nephropathy","volume":"28","author":"Wu","year":"2023","journal-title":"Eur J Med Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with igA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf154","article-title":"Efficacy and safety of telitacicept in IgA nephropathy: real-world study outcomes","volume":"18","author":"Weng","year":"2025","journal-title":"Clin Kidney J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2025.2449580","article-title":"Efficacy and safety of telitacicept in IgA nephropathy: a real-world study","volume":"47","author":"Dong","year":"2025","journal-title":"Ren Fail"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1642137","article-title":"Efficacy and safety of telitacicept in the treatment of IgA nephropathy: a single-center, real-world study","volume":"16","author":"Tao","year":"2025","journal-title":"Front Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with igA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with igA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Rovin","year":"2025","journal-title":"Kidney Int"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e2254054","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive igA nephropathy: A randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.11.027","article-title":"Mycophenolate mofetil combined with prednisone versus full-dose prednisone in igA nephropathy with active proliferative lesions: A randomized controlled trial","volume":"69","author":"Hou","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/iji.12561","article-title":"Immunological drivers of IgA nephropathy: Exploring the mucosa-kidney link","volume":"49","author":"Selvaskandan","year":"2022","journal-title":"Int J Immunogenet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000540326","article-title":"Efficacy and safety of telitacicept in igA nephropathy: A retrospective, multicenter study","volume":"149","author":"Liu","year":"2025","journal-title":"Nephron"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf261","article-title":"Telitacicept versus mycophenolate mofetil in IgA nephropathy: a real-world comparative study of efficacy, renal outcomes and safety","volume":"18","author":"He","year":"2025","journal-title":"Clin Kidney J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/2040622319887875","article-title":"The effectiveness and safety of full-dose versus half-dose corticosteroid plus renin-angiotensin system blockers for IgA nephropathy","volume":"10","author":"Wang","year":"2019","journal-title":"Ther Adv Chronic Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.10.015","article-title":"Mycophenolate mofetil and steroid for treatment of patients with igA nephropathy","volume":"9","author":"Miao","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10238-025-01829-2","article-title":"Telitacicept plus low-dose mycophenolate mofetil in the treatment of IgA nephropathy: a retrospective study","volume":"25","author":"Shu","year":"2025","journal-title":"Clin Exp Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-025-04708-w","article-title":"Efficacy and safety of low- to medium-dose telitacicept in adults with high-risk progressive IgA nephropathy: a retrospective real-world study","volume":"17","author":"Pei","year":"2025","journal-title":"BMC Nephrol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.01.014","article-title":"Treatment of patients with IgA nephropathy: a call for a new paradigm","volume":"107","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"key":"B30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000529650","article-title":"Clinical significance of persistent hematuria degrees in primary igA nephropathy: A propensity score-matched analysis of a 10-year follow-up cohort","volume":"54","author":"Huang","year":"2023","journal-title":"Am J Nephrol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf210","article-title":"Efficacy and safety of telitacicept in adult igA vasculitis nephropathy","volume":"6","author":"Zhang","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.01.003","article-title":"Effect of telitacicept on circulating gd-igA1 and igA-containing immune complexes in igA nephropathy","volume":"9","author":"Zan","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf153","article-title":"Kinetics of CD19(+) B-cell depletion post-rituximab in membranous nephropathy","volume":"18","author":"Sevinc","year":"2025","journal-title":"Clin Kidney J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/nep.14367","article-title":"B cell targeting in IgA nephropathy","author":"Suzuki","year":"2024","journal-title":"Nephrol (Carlton)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1740891\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T06:51:55Z","timestamp":1770792715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1740891\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2026.1740891"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1740891","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"article-number":"1740891"}}